NEW YORK (
CHANGE IN RATINGS
Abercrombie & Fitch
downgraded to hold at TheStreet Ratings.
downgraded at Dahlman from Buy to Hold, Dahlman Rose said. Valuation call as earnings momentum is slowing.
downgraded at BofA/Merrill to Neutral, Bank of America/Merrill Lynch said. Growth appears to be decelerating. $31 price target.
(AMZN - Get Report)
downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Company is going through a business shift and is facing increased operating risks.
downgraded at Argus from Buy to Hold, Argus said. Valuation call, as NBC Universal will likely continue to drag on business.
downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company is leveraged to lower farm cash flow.
downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $16 price target.
upgraded at Baird from Neutral to Outperform, Robert Baird said. $53 price target. Company posted a strong quarter and has several potential near-term catalysts.
Itron upgraded at ThinkEquity from Hold to Buy, ThinkEquity said. $47 price target. Company is restructuring and building operating momentum.
downgraded at BofA/Merrill from Buy to Neutral, Bank of America/Merrill Lynch said. Estimates also cut, as the company is facing increased competition. $16.50 price target.
(PBR - Get Report)
downgraded at Societe Generale from Buy to Hold, Societe Generale said. $31 price target. Downstream business remains a drag.
(PHM - Get Report)
downgraded at UBS to Neutral from Buy, UBS said. $9 price target. Improvements priced in.
upgraded at Argus from Hold to Buy, Argus Research said. $202 price target. Company is expanding its geography and new products are driving growth.
downgraded at JMP from Outperform to Market Perform, JMP Securities said. Doc Fix bill may not help the company
downgraded at Canaccord to Hold, Canaccord Genuity said. $84 price target. Valuation call, as the company is facing higher near-term costs.
STOCK COMMENTS / EPS CHANGES
numbers raised at Guggenheim. Shares of AXP now seen reaching $60, according to Guggenheim. Estimates also increased, as the company has solid operating leverage. Buy rating.